Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laboratorios liconsa s.a. - metylfenidathydroklorid - depottablett - 18 mg - laktosmonohydrat hjälpämne; metylfenidathydroklorid 3,24 mg aktiv substans; metylfenidathydroklorid 14,76 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laboratorios liconsa s.a. - metylfenidathydroklorid - depottablett - 27 mg - laktosmonohydrat hjälpämne; metylfenidathydroklorid 4,86 mg aktiv substans; metylfenidathydroklorid 22,14 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laboratorios liconsa s.a. - metylfenidathydroklorid - depottablett - 36 mg - metylfenidathydroklorid 29,52 mg aktiv substans; laktosmonohydrat hjälpämne; metylfenidathydroklorid 6,48 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laboratorios liconsa s.a. - metylfenidathydroklorid - depottablett - 54 mg - metylfenidathydroklorid 44,28 mg aktiv substans; laktosmonohydrat hjälpämne; metylfenidathydroklorid 9,72 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

phytopharm kleka spolka akcyjna - hedera helix (murgröna) torkat blad; torrt extrakt (4-8:1); etanol 36 % - sirap - kaliumsorbat hjälpämne; hedera helix (murgröna) torkat blad; torrt extrakt (4-8:1); etanol 36 % 8,25 mg aktiv substans; sorbitol hjälpämne

Europeiska unionen - svenska - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belimumab - lupus erythematosus, systemic - immunsuppressiva - benlysta är indicerat som tillägg på terapi hos patienter i åldern 5 år och äldre med aktiva, positiva autoantikroppar systemisk lupus erythematosus (sle) med en hög grad av sjukdomsaktivitet (e. positiv anti-dsdna och låg komplement) trots standardbehandling. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Europeiska unionen - svenska - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, systemic - immunsuppressiva - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laboratorios liconsa s.a. - metylfenidathydroklorid - depottablett - 45 mg - laktosmonohydrat hjälpämne; metylfenidathydroklorid 36,9 mg aktiv substans; metylfenidathydroklorid 8,5 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graftförkastning - immunsuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Europeiska unionen - svenska - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - immunsuppressiva - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).